GlaxoSmithKline Uses Clinical Graphics Solution Developed by Insightful Corporation
29 Avril 2008 - 3:00PM
Business Wire
Insightful Corporation (NASDAQ:IFUL), a leading provider of
predictive analytics and reporting solutions, announced today that
GlaxoSmithKline (GSK), one of the world�s leading research-based
pharmaceutical and healthcare companies, is using a clinical
graphics solution developed by Insightful and S-PLUS�, Insightful�s
software platform for statistical data analysis and predictive
analytics, to speed the design, analysis, and reporting of clinical
trial data. "We are committed to this S-PLUS graphics solution to
assist our statisticians and scientists in understanding our data,
and to improve the communication of results," said Dr. Roger F.
Liddle, Vice President of Discovery Biometrics at GSK and sponsor
of GSK�s clinical graphics initiative. �As of end of 2007, we have
over 200 statisticians, programmers and epidemiologists trained. We
are seeing significant uptake of the S-PLUS graphics solution, with
the majority of users finding it an easy way to produce high
quality graphs. The clinical graphics our staff are producing are
being used by GSK statisticians, clinicians, and publishing staff
in several critical areas, including data analysis, presentation,
submission, and publication.� Insightful�s clinical graphics
solutions are designed to enable effective communication of
clinical data in journals, presentations, and regulatory
submissions through point-and-click creation of advanced graphics
and seamless integration with existing exploratory, presentation,
and production reporting environments. Important benefits of these
clinical graphics solutions include the ease of use for those
without specialized programming skills and streamlined graphics
production across all clinical and reporting areas, minimizing the
time and cost incurred by expensive and scarce statistical
programming resources. GSK is employing Insightful�s S-PLUS
platform and advanced statistical graphics libraries, including
Trellis� technology and a comprehensive graphics taxonomy
collection. These libraries deliver industry-standard graphics for
interpreting and communicating information in clinical data. "GSK
is a world-recognized leader in the use of statistical graphics for
analysis, presentation, and communication of information in
clinical data," said Jeff Coombs, president and CEO of Insightful.
"The clinical graphics solution that we built for GSK on top of our
S-PLUS platform provides them with an integrated solution for
extracting and communicating information in clinical data across
their organization and to their clinical and regulatory partners.
We are pleased to have the opportunity to assist GSK in this core
function of their business." ABOUT INSIGHTFUL Insightful
Corporation (NASDAQ:IFUL) is a provider of predictive analytics and
reporting solutions. Insightful products S-PLUS�, Insightful Miner�
and S-PLUS� Enterprise Server allow companies to perform
sophisticated statistical data analysis and data mining and create
high-quality graphics and reports. Insightful has been delivering
industry-leading, high-ROI solutions to thousands of companies in
financial services, life sciences, telecommunications, and
manufacturing, plus government and research institutions, for 20
years. Headquartered in Seattle, Insightful has offices in New
York, North Carolina, the United Kingdom, Switzerland, France and
Hong Kong, with distributors around the world. For more
information, visit www.insightful.com, email info@insightful.com or
call 1-800-569-0123. Note to Investors � Forward Looking Statements
This press release contains forward-looking statements, including
statements about the expected value of Insightful�s clinical
graphics solutions to GSK and other customers. Forward-looking
statements are based on the judgment and opinions of management at
the time the statements are made. Inaccurate assumptions and known
and unknown risks and uncertainties can affect the accuracy of
forward-looking statements. Actual results could differ materially
from those expressed or implied by the forward-looking statements
for a number of reasons, including, without limitation, the risk
that Insightful�s clinical graphics solutions do not perform as
designed and expected or do not achieve market acceptance. More
detailed information regarding these and other factors that could
affect actual results is set forth in our filings with the
Securities and Exchange Commission, including our most recent
report on Form 10-QSB. You should not unduly rely on these
forward-looking statements, which apply only as of the date of this
release. We undertake no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date of this release or to reflect the
occurrence of anticipated events.
Insightful (NASDAQ:IFUL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Insightful (NASDAQ:IFUL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024